Breaking News Instant updates and real-time market news.

AGN

Allergan

$152.44

-1.93 (-1.25%)

, AMGN

Amgen

$171.53

-4.4 (-2.50%)

12:25
05/15/18
05/15
12:25
05/15/18
12:25

Piper Jaffray specialty pharma analysts to hold analyst/industry conference call

The Specialty Pharmaceuticals & Biotech Analysts Research Teams, along with a featured expert KOL in the chronic migraine field, discuss acute treatment of migraine and migraine prophylaxis, in both chronic and episodic patients, on an analyst/industry conference call to be held on May 15 at 1 pm.

AGN

Allergan

$152.44

-1.93 (-1.25%)

AMGN

Amgen

$171.53

-4.4 (-2.50%)

SUPN

Supernus

$58.05

0.9 (1.57%)

TEVA

Teva

$20.26

-0.11 (-0.54%)

LLY

Eli Lilly

$82.40

-0.68 (-0.82%)

  • 15

    May

  • 15

    May

  • 17

    May

  • 18

    May

  • 21

    May

  • 22

    May

  • 28

    May

  • 05

    Jun

  • 07

    Jun

  • 16

    Jun

AGN Allergan
$152.44

-1.93 (-1.25%)

05/01/18
MZHO
05/01/18
NO CHANGE
Target $150
MZHO
Neutral
Allergan price target lowered to $150 from $185 at Mizuho
Mizuho analyst Irina Koffler lowered her price target for Allergan to $150 citing a weaker growth outlook following the company's Q1 results. The analyst believes her new price target reflects a "more realistic growth outlook for the existing business." She keeps a Neutral rating on Allergan.
05/01/18
DBAB
05/01/18
NO CHANGE
Target $210
DBAB
Buy
Deutsche continues to like the setup for Allergan shares
Deutsche Bank analyst Gregg Gilbert acknowledges the uncertainty regarding Allergan's strategic review but says he continues to like the setup for the shares. The analyst his earnings estimates based primarily on the Q1 outperformance and accelerated share repurchase. He keeps a Buy rating on Allergan with a $210 price target.
05/01/18
WELS
05/01/18
NO CHANGE
Target $240
WELS
Outperform
Allergan price target lowered to $240 from $245 at Wells Fargo
Wells Fargo analyst David Maris lowered his price target for Allergan to $240 from $245 following Q1 results and as investors seem to remain uncertain about Allergan's strategic direction. The analyst reiterates an Outperform rating on the shares.
05/07/18
CANT
05/07/18
NO CHANGE
CANT
Cantor positive on Evolus, Revance on potential to take Botox share
The potential launches of Evolus' (EOLS) DWP-450 in 2018 and Revance Therapeutics' (RVNC) RT002 in 2020 has investors wondering if less expensive and longer lasting toxins could take meaningful share away from Allergan's (AGN) Botox, Cantor Fitzgerald analyst Louise Chen tells investors in a research note. After speaking with two physicians who use 500-864 vials of Botox per year in their practices, the analyst reiterates Overweight ratings on Evolus and Revance and a Neutral rating on Allergan. Both doctors, who use Allergan's Botox in 95%-plus of their patients, said they would switch a large amount of their practice over to less expensive and/or longer acting toxins, if they are approved, Chen writes.
AMGN Amgen
$171.53

-4.4 (-2.50%)

03/12/18
MSCO
03/12/18
NO CHANGE
Target $196
MSCO
Overweight
Enbrel IPR denials lift an overhang on Amgen, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison noted that on Friday the USPTO's Patent Trial and Appeal Board denied the institution of two IPRs filed by Coherus Biosciences (CHRS) against Enbrel patients 8,063,182 and 8,163,522, which he said removes one near-term overhang on Amgen (AMGN) shares. Harrison noted that he has always viewed the IPRs as a greater risk to Enbrel than a District Court case being brought by Novartis' (NVS) Sandoz division, which is set to begin its trial on April 17, as he has always seen a potential settlement with Sandoz as a reasonable possibility. The analyst keeps his Overweight rating and $196 price target on Amgen shares.
04/25/18
RBCM
04/25/18
NO CHANGE
Target $183
RBCM
Sector Perform
Amgen price target lowered to $183 from $189 at RBC Capital
RBC Capital analyst Kennen MacKay lowered his price target on Amgen to $183 and kept his Sector Perform rating after the company's Q1 results. The analyst notes that despite the earnings beat and higher FY18 midpoint guidance, he is more cautious as Amgen's base products drove the revenue gains. MacKay adds that he remains concerned by the competitive threats to Amgen's legacy business.
04/25/18
COWN
04/25/18
NO CHANGE
Target $204
COWN
Outperform
Amgen shares remain undervalued, says Cowen
Cowen analyst Eric Schmidt noted Amgen reported better than expected Q1 results and tweaked the lower end of its revenue guidance. The analyst said the guidance appears conservative in light of sales trends. Schmidt reiterated his Outperform rating and $204 price target on Amgen, noting he believes the shares remain undervalued.
05/15/18
MZHO
05/15/18
NO CHANGE
Target $200
MZHO
Buy
Amgen buyback activity could buoy shares, says Mizuho
Mizuho analyst Salim Syed says that for Amgen to buy back the $2B-$4B of its own stock this quarter, as it said it would do, it would have to make up 5%-11% of daily volume traded every day in the current quarter. The analyst is "not fully convinced this math has been entirely digested by the Street." This could potentially act as a buoy for the stock this quarter, Syed tells investors in a research note. The analyst keeps a Buy rating on the shares with a $200 price target.
SUPN Supernus
$58.05

0.9 (1.57%)

02/01/18
BREN
02/01/18
INITIATION
Target $66
BREN
Buy
Supernus initiated with a Buy at Berenberg
Berenberg analyst Patrick Trucchio initiated Supernus with a Buy and $66 price target.
04/18/18
JEFF
04/18/18
NO CHANGE
Target $54
JEFF
Buy
Supernus on track to exceed guidance, says Jefferies
After hosting investor meetings with management, Jefferies analyst David Steinberg believes Supernus Pharmaceuticals looks on track to exceed guidance for the year. Supernus will likely buy an asset this year, with a focus likely on a pipeline candidates versus drug on the market, Steinberg tells investors in a research note. He notes the company has a $640M war chest. The analyst keeps a Buy rating on the shares with a $54 price target.
12/04/17
JANY
12/04/17
UPGRADE
Target $47
JANY
Buy
Supernus upgraded to Buy from Neutral at Janney Capital
Janney Capital analyst Ken Trbovich upgraded Supernus to Buy from Neutral, calling it the best positioned among the companies he covers to be an immediate beneficiary of lower U.S. corporate tax rates, which now appear highly likely for 2018 following the passage of tax bills in both the Senate and House. Reducing the Federal corporate tax rate from 35% to 22% would boost his 2018 EPS estimate for Supernus to $1.72 from $1.48 per share, noted Trbovich, who reiterated a $47 fair value estimate on the stock.
11/08/17
STFL
11/08/17
UPGRADE
Target $47
STFL
Buy
Supernus upgraded to Buy from Hold at Stifel
Stifel analyst Annabel Samimy upgraded Supernus Pharmaceuticals to Buy with a price target of $47 citing valuation. The analyst recommends buying the shares following yesterday's post-earnings weakness. Investor focus on the spike in gross-net in Q3 clouds the company's "stellar and consistent execution" and predictability in meeting expectations, Samimy tells investors in a research note after the shares fell 11%.
TEVA Teva
$20.26

-0.11 (-0.54%)

04/30/18
DBAB
04/30/18
NO CHANGE
Target $22
DBAB
Buy
Deutsche raises Valeant price target on extended Xifaxan exclusivity
The stay in the Xifaxan litigation between Valeant Pharmaceuticals (VRX) and Teva (TEVA) was recently extended to July 30, 2018 from April 30, 2018, and may be extended further, Deutsche Bank analyst Gregg Gilbert tells investors in an intraday research note. According to the court docket, the companies agreed to extend the stay "because the facts and circumstances that warranted a stay as of May 15, 2017 have not materially changed," Gilbert adds. He previously modeled Xifaxan exclusivity through 2024, but pushed that out one more year saying Teva "does not yet appear to have clarity on the path forward for its generic filing." The exclusivity extension to 2025 on Valeant's largest product pushes the analyst's price target for the shares to $22 from $20. The stock in midday trading is up 19c to $18.26. Gilbert looks forward to an update from Teva when the company reports on May 3 and continues to like the risk/reward for Valeant. He keeps a Buy rating on the shares.
05/07/18
FBCO
05/07/18
NO CHANGE
Target $23
FBCO
Outperform
Teva turnaround story appears generally on track, says Credit Suisse
Credit Suisse analyst Vamil Divan believes Teva's Q1 earnings were "solid" and sees his bullish thesis on the company as being on track. The analyst notes that the company's restructuring program is proceeding in line with its prior guidance and his expectations, if even a bit ahead of schedule. Divan reiterates an Outperform rating and $23 price target on the shares.
04/27/18
JEFF
04/27/18
NO CHANGE
Target $105
JEFF
Buy
Neurocrine's Ingrezza can beat Q1 estimates, says Jefferies
Jefferies analyst Biren Amin says his firm's fifth proprietary survey on tardive dyskinesia reaffirms that Neurocrine Biosciences' (NBIX) Ingrezza is leading Teva's (TEVA) Austedo in market share for both moderate-severe and mild cases. The analyst thinks Ingrezza can modestly beat consensus estimates for Q1. He keeps a Buy rating on Neurocrine shares with a $105 price target.
05/03/18
WELS
05/03/18
NO CHANGE
Target $16.5
WELS
Underperform
Teva Q1 'just what investors wanted,' says Wells Fargo
Wells Fargo analyst David Maris believes this quarter is exactly the quarter investors wanted out of Teva, namely progress on the cost cutting and raised guidance on the back of a business that is still facing a significant decline given a tough U.S. generics environment and generic Copaxone pressures. The analyst reiterates an Underperform rating and $16.50 price target on the shares.
LLY Eli Lilly
$82.40

-0.68 (-0.82%)

04/25/18
DBAB
04/25/18
NO CHANGE
DBAB
Hold
Merck may need to reassess animal health unit, says Deutsche Bank
While Merck (MRK) describes its animal health unit as a key growth driver and an important part of the company, it remains to be seen whether investors will continue to accept this as a reason for the business to remain within the company, Deutsche Bank analyst Gregg Gilbert tells investors in a research note. He believes the unit is potentially undervalued. Given Zoetis' (ZTS) success as a company and a stock, and Eli Lilly's (LLY) ongoing review of strategic options for its Elanco Animal Health business, Gilbert conducted a preliminary separation analysis of Merck's animal health unit. The analysis suggests that a separation could be meaningfully accretive to earnings. The analyst keeps a Hold rating on Merck.
04/23/18
RBCM
04/23/18
NO CHANGE
RBCM
Outperform
Incyte AdCom meeting going more favorably than docs suggested, says RBC Capital
RBC Capital analyst Brian Abrahams said the FDA advisory committee meeting for baricitinib, a rheumatoid arthritis treatment developed by Incyte (INCY) and submitted for review by Eli Lilly (LLY), seems "considerably less negative" than the briefing documents for the meeting had suggested. He sees the tone of the panel and the panelist Q&A suggesting a high likelihood that baricitinib will be approved, with the potential still existing that even a 4mg version could be approved in some form. Abrahams has an Outperform rating and $75 price target on Incyte shares.
04/13/18
04/13/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: Netflix (NFLX) upgraded to Buy from Hold at Deutsche Bank with analyst Bryan Kraft saying he underestimated the market's willingness to underwrite several years of negative free cash flow to drive growth. 2. Eli Lilly (LLY) upgraded to Market Perform from Underperform at BMO Capital with analyst Alex Arfaei saying he believes that his previously expressed concerns around the downside risks for Humalog, cautious outlook for Vernezio, and uncertainty around Bari are "mostly reflected" in the stock, with more balance in risk-reward going forward. 3. Willis Towers Watson (WLTW) upgraded to Buy from Hold at Sandler O'Neill with analyst Paul Newsome saying he is making a valuation call with the stock down to "both absolute and relative valuations that we have not seen since there were significant concerns about the Willis/Towers Watson merger and the company's ability to generate organic growth." 4. Shaw Communications (SJR) upgraded to Buy from Hold at Canaccord and to Outperform from Sector Perform at Scotiabank. 5. eBay (EBAY) upgraded to Buy from Neutral at Monness Crespi with analyst Jim Chartier saying eBay's structured data initiatives have meaningfully improved the eBay marketplace experience for buyers and sellers, resulting in gross merchandise value inflecting to up 7% in the fourth quarter of 2017 from up 1% in the third quarter of 2016. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/13/18
BMOC
04/13/18
UPGRADE
Target $79
BMOC
Market Perform
Eli Lilly upgraded to Market Perform at BMO Capital on valuation
As reported earlier, BMO Capital analyst Alex Arfaei upgraded Eli Lilly to Market Perform from Underperform and raised his price target to $79 from $74. The analyst believes that his previously expressed concerns around the downside risks for Humalog, cautious outlook for Vernezio, and uncertainty around Bari are "mostly reflected" in the stock, with more balance in risk-reward going forward. While he anticipates 2018 to be volatile as maturing diabetes franchise constrains the company's growth plans, Arfaei also sees some tailwinds for Eli Lilly around continued strong growth of Trulicity, further growth of Taltz, Jardiance, and Basglar, as well as potential divestiture of Elanco.

TODAY'S FREE FLY STORIES

SKYAY

Sky

$0.00

(0.00%)

, DIS

Disney

$109.55

0.18 (0.16%)

04:51
09/19/18
09/19
04:51
09/19/18
04:51
Downgrade
Sky, Disney, Comcast, 21st Century Fox rating change  »

Sky downgraded to Neutral…

SKYAY

Sky

$0.00

(0.00%)

DIS

Disney

$109.55

0.18 (0.16%)

CMCSA

Comcast

$37.74

0.78 (2.11%)

FOXA

21st Century Fox

$44.54

-0.17 (-0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

03:50
09/19/18
09/19
03:50
09/19/18
03:50
General news
FX Action: USD-CAD is down for a second day »

FX Action: USD-CAD is…

02:40
09/19/18
09/19
02:40
09/19/18
02:40
General news
FX Update: The Dollar has continued to trade with a softening bias »

FX Update: The Dollar…

01:55
09/19/18
09/19
01:55
09/19/18
01:55
General news
Asian stock markets have rallied »

Asian stock markets have…

23:35
09/18/18
09/18
23:35
09/18/18
23:35
General news
Bank of Japan maintained the -0.1% policy rate »

Bank of Japan maintained…

INGIY

Ingenico

$0.00

(0.00%)

20:59
09/18/18
09/18
20:59
09/18/18
20:59
Upgrade
Ingenico rating change at Goldman Sachs »

Ingenico upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

MSFT

Microsoft

$113.24

1.05 (0.94%)

20:52
09/18/18
09/18
20:52
09/18/18
20:52
Hot Stocks
Microsoft announces new AI and mixed reality business applications for Dynamics »

In its official blog,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 28

    Oct

  • 03

    Mar

BWA

BorgWarner

$42.99

-1.17 (-2.65%)

19:34
09/18/18
09/18
19:34
09/18/18
19:34
Hot Stocks
BorgWarner sees operating margins in low-13% by FY23 vs 12.4% in FY17 »

As part of its Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 25

    Oct

JLL

Jones Lang LaSalle

$144.15

0.795 (0.55%)

19:31
09/18/18
09/18
19:31
09/18/18
19:31
Hot Stocks
Jones Lang LaSalle CFO Christie Kelly resigns »

Jones Lang LaSalle…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

RACE

Ferrari

$138.31

5.465 (4.11%)

19:24
09/18/18
09/18
19:24
09/18/18
19:24
Earnings
Ferrari sees FY18 revenue over EUR3.4B »

As part of its Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

SMRT

Stein Mart

$1.97

-0.09 (-4.37%)

, INAP

Internap

$12.39

-0.33 (-2.59%)

19:02
09/18/18
09/18
19:02
09/18/18
19:02
Hot Stocks
Fly Intel: After Hours Movers »

HIGHER: Stein Mart (SMRT)…

SMRT

Stein Mart

$1.97

-0.09 (-4.37%)

INAP

Internap

$12.39

-0.33 (-2.59%)

TRVG

Trivago

$5.13

0.26 (5.34%)

PRQR

ProQR Therapeutics

$20.25

-1.4 (-6.47%)

MSFT

Microsoft

$113.24

1.05 (0.94%)

EVOP

EVO Payments

$26.27

-0.42 (-1.57%)

TSM

TSMC

$43.57

-0.2 (-0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 28

    Oct

  • 12

    Nov

  • 15

    Nov

  • 03

    Mar

  • 21

    Sep

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$290.96

1.55 (0.54%)

18:58
09/18/18
09/18
18:58
09/18/18
18:58
Periodicals
China to place new tariffs on $60B in U.S. exports, WSJ says »

China's government…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$290.96

1.55 (0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SQ

Square

$87.97

1.1 (1.27%)

18:55
09/18/18
09/18
18:55
09/18/18
18:55
Periodicals
Square seeks to bring 'omnichannel' experience to restaurants, CNBC says »

Square CFO Sarah Friar…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 19

    Sep

  • 20

    Sep

  • 26

    Sep

MSFT

Microsoft

$113.24

1.05 (0.94%)

18:48
09/18/18
09/18
18:48
09/18/18
18:48
Hot Stocks
Microsoft confirms raised quarterly dividend payment to 46c from 42c per share »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 28

    Oct

  • 03

    Mar

KL

Kirkland Lake Gold

$17.57

-0.64 (-3.51%)

18:39
09/18/18
09/18
18:39
09/18/18
18:39
Hot Stocks
Kirkland Lake Gold acquires shares of Osisko Mining »

Kirkland Lake Gold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

MSFT

Microsoft

$113.24

1.05 (0.94%)

18:39
09/18/18
09/18
18:39
09/18/18
18:39
Hot Stocks
Breaking Hot Stocks news story on Microsoft »

Microsoft raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 28

    Oct

  • 03

    Mar

OMAB

OMA Airports

$56.18

2.13 (3.94%)

18:23
09/18/18
09/18
18:23
09/18/18
18:23
Downgrade
OMA Airports rating change at Santander »

OMA Airports downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$113.41

-0.03 (-0.03%)

18:01
09/18/18
09/18
18:01
09/18/18
18:01
Hot Stocks
Celanese raises prices for acetate tow in Eastern Europ and Asia by $1/kg »

Celanese Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WYNN

Wynn Resorts

$132.97

0.56 (0.42%)

17:58
09/18/18
09/18
17:58
09/18/18
17:58
Periodicals
Wynn sued over allegations of rigging Boston casino bid, Bloomberg says »

Wynn Resorts and former…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Trust

$113.43

-0.18 (-0.16%)

17:48
09/18/18
09/18
17:48
09/18/18
17:48
Hot Stocks
SPDR Gold Trust holdings fall to 742.23MT from 742.53MT »

This is the lowest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JAZZ

Jazz Pharmaceuticals

$161.89

0.92 (0.57%)

17:35
09/18/18
09/18
17:35
09/18/18
17:35
Recommendations
Jazz Pharmaceuticals analyst commentary at BMO Capital »

Jazz Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 27

    Oct

  • 27

    Nov

  • 20

    Dec

RIG

Transocean

$11.93

0.335 (2.89%)

17:29
09/18/18
09/18
17:29
09/18/18
17:29
Initiation
Transocean initiated at Morgan Stanley »

Transocean initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NE

Noble Corp.

$6.15

0.19 (3.19%)

17:26
09/18/18
09/18
17:26
09/18/18
17:26
Initiation
Noble Corp. initiated at Morgan Stanley »

Noble Corp. initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

CCOEY

Capcom

17:24
09/18/18
09/18
17:24
09/18/18
17:24
Periodicals
Capcom shutting down Vancouver studio, Kotaku says »

Capcom Vancouver,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBY

Best Buy

$77.70

0.67 (0.87%)

17:24
09/18/18
09/18
17:24
09/18/18
17:24
Syndicate
Breaking Syndicate news story on Best Buy »

Best Buy files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.